KNSA vs REGN: fair value comparison
Kiniksa Pharmaceuticals International, plc and Regeneron Pharmaceuticals, Inc. · Updated 2026-09-12
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, REGN currently sits closer to the top of our discount ranking.
| KNSA | REGN | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $79.28 | $781.49 |
| 12-month range | $37.47–$79.28 | $600.66–$823.82 |
| Sector rank | #69 of 113 Healthcare | #66 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: KNSA fair value analysis · REGN fair value analysis